Filing Flows › Rani Therapeutics Holdings (RANI) › Q3 2026
Rani Therapeutics Holdings (RANI) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Rani Therapeutics Holdings (RANI) reported revenue of $1.7M for the third quarter 2026 (Q3 2026) and -0.1% from the quarter before. Operating margin was -540.3%, net loss $8.8M (515.9% of revenue).
Rani Therapeutics Holdings, Q3 2026: revenue $1.7M, operating margin -540.3%, net loss $8.8M, operating cash flow −$7.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | -0.1% | — |
| Operating profit | −$9.2M | — | — |
| Net earnings | −$8.8M | — | — |
| Operating cash flow | −$7.8M | — | — |
What changed
Revenue was $1.7M in Q3 2026, roughly flat from the previous quarter.
Operating costs exceeded revenue by $9.2M, an operating margin of -540.3%. The quarter ended with a net loss of $8.8M, wider than the previous quarter's $8.4M loss. Minority interests bore $1.1M of it: to shareholders the quarter was a loss of $7.7M.
Operating cash flow was −$7.8M. Non-cash charges added back $123K of depreciation and amortization and $2.2M of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $183K exceeded it, leaving free cash flow of −$7.9M.
Questions
What was Rani Therapeutics Holdings' revenue in the third quarter 2026?
Rani Therapeutics Holdings (RANI) reported revenue of $1.7M for the third quarter 2026 (Q3 2026) and -0.1% from the quarter before.
Was Rani Therapeutics Holdings profitable in the third quarter 2026?
Operating loss was $9.2M (-540.3% of revenue) and net loss $8.8M.